IM-101 is a humanized monoclonal antibody targeting complement C5 with high affinity. In the recently concluded Phase 1 clinical trial, ...

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2 A phase II trial has recently been ...

In 2023, there were an estimated 44 thousand total incident cases of kidney transplants across the 7MM, with the number ...

The Global Monoclonal Antibody Therapeutics Market is valued at approximately USD 205.09 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.0% over the forecast ...

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where ...

Accumulating experimental evidence indicates that overexpression of the oncogenic receptor tyrosine kinase, Axl, plays a key role in the tumorigenesis and metastasis of various types of cancer. The ...

Both small animal models and microphysiological systems gain in sophistication and value as they expedite in vivo preclinical testing.

Abstract. Breast cancer is the most common cancer in women diagnosed in the U.S. and worldwide. Obesity increases breast cancer risk without clear underlying molecular mechanisms. Our studies ...

Sibeprenlimab is an investigational monoclonal antibody that selectively binds to and inhibits the activity of APRIL and plays a key role in the 4-hit ... By reducing the production of Gd-IgA1, ...

Monoclonal antibodies (or mAbs) are special proteins made by identical immune cells that all come from the same original cell. These proteins are designed to recognize and attach to specific targets, ...

Now approved for its fifth indication, mepolizumab, a monoclonal antibody that targets interleukin-5, is indicated as an add-on maintenance treatment for adults with inadequately controlled COPD ...